|会社名||Boston Scientific Corp. （BSX ボストン・サイエンティフィック）|
|業種||先端医療機器_テクノロジ― 医療関連（Health Care）|
|概要||事業概要 ボストン・サイエンティフィック（Boston Scientific Corporation）はインターベンション医療専門分野に使用される医療機器の開発・製造・販売に従事する会社である。同社はインターベンション心臓病学、心臓リズム管理、内視鏡検査、末梢介入、泌尿器と骨盤の健康、神経調節、電気生理学という7つの事業によって製品を提供する。同社は3つの事業区分により構成される。心臓血管事業は介入的心臓病学と周辺介入事業を含む。リズム管理事業は心臓リズム管理と電気生理学事業を含む。MedSurg事業は内視鏡検査、泌尿器科と骨盤の健康検査、神経変性治療を含む。インターベンショナル・カーディオロジー製品はバルーン・カテーテル、回転アテローム切除システム、ガイド・ワイヤー、ガイド・カテーテル、塞栓防止装置、経皮的冠動脈形成術（PTCA）に使用される診断用カテーテルを含む。 ボストン・サイエンティフィックは米国の医療機器メ―カ―。主要製品は不整脈の治療用の植込み型除細動器とペ―スメ―カ―、ステント、バル―ンカテ―テルなどを提供。呼吸器と消化器分野に内視鏡、泌尿器・婦人科用の尿路結石症、子宮出血治療用製品、疼痛治療用の脊髄電気装置や血管内超音波装置も扱う。事業は米国、欧州、中東、アフリカ、日本で展開。 Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, The company advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.|
|代表者氏名||Michael F. Mahoney|
|代表者役職名||Chairman of the Board President Chief Executive Officer|
|決算概要||決算概要 BRIEF: For the fiscal year ended 31 December 2018 Boston Scientific Corporation revenues increased 9% to $9.82B. Net income applicable to common stockholders excluding extraordinary items increased 66% to $1.6B. Revenues reflect Rhythm and Neuro segment increase of 40% to $3.04B Cardiovascular segment increase of 8% to $3.78B United States segment increase of 7% to $5.54B.|
Boston Scientific to Participate in J.P. Morgan Healthcare Conference and Announces Conference Call Discussing Fourth Quarter 2022 Results 2023/01/03 14:30:00 PR Newswire
MARLBOROUGH, Mass., Jan. 3, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 in San Francisco, California. Mike Mahoney, chairman and chief executive officer, will present at…
Global and United States Thrombolysis Treatment Device Market to Witness Huge Growth by Key Players: Terumo, Boston Scientific, Teleflex, Penumbra, Vascular Solutions 2022/12/22 08:49:14 OpenPR
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Thrombolysis Treatment Device industry. This wide-ranging market research report acts as a backbone for the success of
Why Analysts Are Pricing in a Recession: Upgrades and Downgrades of Boston Scientific, Conagra, Target and More – 24/7 Wall St. 2022/12/20 16:20:30 24/7 Wall street
Tuesday’s additional top analyst upgrades and downgrades were on BJ’s Wholesale Club, Boston Scientific, Conagra Brands, NetApp, Norfolk Southern, Spirit Airlines, Stitch Fix, Target, Union Pacific and more.
Citi Resumes Boston Scientific at Buy 2022/12/19 16:54:01 Investing.com
Boston Scientific Corporation – Consensus Indicates Potential 6.5% Upside 2022/12/19 14:34:20 DirectorsTalk
Boston Scientific Corporation with ticker code (BSX) now have 25 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 54 and 45 with a mean TP of 49.32. With the stocks previous close at 46.32 this now indicates there is a potential upside of 6.5%. The day 50 moving average is 43.01 and the 200 moving average now moves to 41.35. The market capitalisation for the company is $65,614m. Find out more information at: https://www.bostonscientific.com [stock_market_widget type="chart" template="basic" color="green" assets="BSX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $69,864m based on the market concensus. Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
Electro-Diagnostic Devices Market Expected to Expand at a Steady 2022-2028 | Medtronic, Abbott, Boston Scientific Corporation, Siemens Medical Solutions 2022/10/04 12:43:05 OpenPR
The global "Electro-Diagnostic Devices Market" report aims to provide a detailed analysis of the factors that influence the global business adoption and segmentation outlook. The detailed information and overview of the global Electro-Diagnostic Devices market report highlight the latest development
Boston Scientific Corporation (NYSE: BSX) Stock Forecast: Potential To Pass $53.00 Within A Year 2022/10/03 17:00:00 Stocks Register
The trading price of Boston Scientific Corporation (NYSE:BSX) floating higher at last check on Monday, October 03, closing at $39.88, 2.97% higher than its previous close. Traders who pay close attention to intraday price movement should know that it has been fluctuating between $38.70 and $39.99. The company’s P/E ratio in the trailing 12-month period … Boston Scientific Corporation (NYSE: BSX) Stock Forecast: Potential To Pass $53.00 Within A Year Read More »
Truveta Announces Collaboration with Boston Scientific 2022/10/03 14:40:00 Accesswire
NORTHAMPTON, MA / ACCESSWIRE / October 3, 2022 / Truveta announced a strategic collaborative agreement with Boston Scientific Corporation whereby Boston Scientific researchers will be able to access data from Truveta that contains deidentified medical records from more than 65 million patients in the United States. According to Truveta, the collaboration seeks to improve long-term patient care and gain insights into health care disparities. Continue reading here. View additional multimedia and more ESG storytelling from Boston Scientific on 3blmedia.com. Contact Info: Spokesperson: Boston Scientific Website: https://www.bostonscientific.com/en-US/Home.html Email: firstname.lastname@example.org SOURCE: Boston Scientific
Boston Scientific Announces Conference Call Discussing Third Quarter 2022 Results 2022/10/03 13:30:00 PR Newswire
MARLBOROUGH, Mass., Oct. 3, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2022 on Wednesday, October 26, 2022 at 8:00 a.m. EDT. The call will be…
Boston Scientific in partnership with Truveta on patient outcomes to improve care (BSX) 2022/09/27 15:25:15 Seeking Alpha
Boston Scientific (BSX) has entered into a collaboration with Truveta, which provides de-identified health data, to analyze patient outcomes related to use of the device companys products.
Thursday’s Top Analyst Upgrades and Downgrades: Abbott Labs, Boeing, Etsy, Kohl’s, Merck, Netflix, Qualcomm and More 2022/07/07 12:53:10 24/7 Wall street
Thursday''s top analyst upgrades and downgrades included Abbott Laboratories, Azul, Boeing, Boston Scientific, Callon Petroleum, Corning, Datadog, Etsy, HCA Healthcare, Kohl''s, Medtronic, Merck, Netflix, Pioneer Natural Resources, Pure Storage, Qualcomm, Sabre and Sysco.
How Is The Market Feeling About Boston Scientific? 2022/06/29 14:03:45 Benzinga
Boston Scientific''s (NYSE: BSX ) short percent of float has risen 25.0% since its last report. The company recently reported that it has 19.02 million shares sold short , which is 1.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.2 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com
Boston Scientific Announces Conference Call Discussing Second Quarter 2022 Results 2022/06/29 13:30:00 PR Newswire
MARLBOROUGH, Mass., June 29, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ending June 30, 2022 on Wednesday, July 27, 2022 at 8:00 a.m. EDT. The call will be…
Global Neurology Devices Market Analysis & Forecasts, 2016-2021, 2021-2026F, 2031F 2022/06/22 10:15:00 Benzinga
DUBLIN , June 22, 2022 /PRNewswire/ -- The "Global Neurology Devices Market Report 2022" report has been added to ResearchAndMarkets.com''s offering. The global neurology devices market is expected to grow from $13.94 billion in 2021 to $15.91 billion in 2022 at a compound annual growth rate (CAGR) of 14.2%. The market is expected to grow to $25.75 billion in 2026 at a compound annual growth rate (CAGR) of 12.8%. Major companies in the neurology devices market include Medtronic Inc., Stryker Corporation, Terumo Corporation, Integra Lifesciences, Boston Scientific Corporation, Penumbra, Inc., B. Braun Group, Nevro, LivaNova, PLC, and Natus Medical. The neurology devices market consists of sales of neurology devices and related services by entities (organizations, sole traders, and partnerships) that produce neurology devices to diagnose and treat neurological diseases. The main types of neurology devices are cerebrospinal fluid management (CSF) devices and equipment, interventional neurology devices and equipment, neurosurgery devices and equipment, and neurostimulation devices.